학술논문
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
Document Type
Article
Author
Robbins, D.W.; Noviski, M.A.; Tan, Y.S.; Konst, Z.A.; Kelly, A.; Auger, P.; Brathaban, N.; Cass, R.; Chan, M.L.; Cherala, G.; Clifton, M.C.; Gajewski, S.; Ingallinera, T.G.; Karr, D.; Kato, D.; Ma, J.; McKinnell, J.; McIntosh, J.; Mihalic, J.; Murphy, B.; Panga, J.R.; Peng, G.; Powers, J.; Perez, L.; Rountree, R.; Tenn-McClellan, A.; Sands, A.T.; Weiss, D.R.; Wu, J.; Ye, J.; Guiducci, C.; Hansen, G.; Cohen, F.
Source
In: Journal of Medicinal Chemistry . (Journal of Medicinal Chemistry, 22 February 2024, 67(4):2321-2336)
Subject
Language
English
ISSN
15204804
00222623
00222623